A Partially Structured Species of β2-Microglobulin Is Significantly Populated under Physiological Conditions and Involved in Fibrillogenesis

The folding of β2-microglobulin (β2-m), the protein forming amyloid deposits in dialysis-related amyloidosis, involves formation of a partially folded conformation named I2, which slowly converts into the native fold, N. Here we show that the partially folded species I2 can be separated from N by ca...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of biological chemistry 2001-12, Vol.276 (50), p.46714-46721
Hauptverfasser: Chiti, Fabrizio, De Lorenzi, Ersilia, Grossi, Silvia, Mangione, Palma, Giorgetti, Sofia, Caccialanza, Gabriele, Dobson, Christopher M., Merlini, Giampaolo, Ramponi, Giampietro, Bellotti, Vittorio
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The folding of β2-microglobulin (β2-m), the protein forming amyloid deposits in dialysis-related amyloidosis, involves formation of a partially folded conformation named I2, which slowly converts into the native fold, N. Here we show that the partially folded species I2 can be separated from N by capillary electrophoresis. Data obtained with this technique and analysis of kinetic data obtained with intrinsic fluorescence indicate that the I2 conformation is populated to ∼14 ± 8% at equilibrium under conditions of pH and temperature close to physiological. In the presence of fibrils extracted from patients, the I2 conformer has a 5-fold higher propensity to aggregate than N, as indicated by the thioflavine T test and light scattering measurements. A mechanism of aggregation of β2-m in vivo involving the association of the preformed fibrils with the fraction of I2 existing at equilibrium is proposed from these results. The possibility of isolating and quantifying a partially folded conformer of β2-m involved in the amyloidogenesis process provides new opportunities to monitor hemodialytic procedures aimed at the reduction of such species from the pool of circulating β2-m but also to design new pharmaceutical approaches that consider such species as a putative molecular target.
ISSN:0021-9258
1083-351X
DOI:10.1074/jbc.M107040200